rs10023464

This is a intergenic variant variant.

▶

GWAS Catalog Trait Associations (2)

Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.

plasma clozapine-to-N-desmethylclozapine ratio measurement

Pardiñas AF et al. “Pharmacogenomic Variants and Drug Interactions Identified Through the Genetic Analysis of Clozapine Metabolism.” The American Journal of Psychiatry 176(6):477-486 (2019)
Allele T
OR —
p 9.0e-66
N 2,989
Large GWAS
European
▶

Research that mentions this SNP (1)

▶
Interaction between genetic variants ofDLGAP3andSLC1A1Affecting the Risk of Atypical Antipsychotics‐Induced Obsessive–Compulsive Symptoms
AssociationN=91Seunghyong Ryu et al.(2011)· American Journal of Medical Genetics Part B: Neuropsychiatric Genetics

This proof-of-concept study examined polygenetic risk scores (PRS) in 91 clozapine-treated schizophrenia patients with obsessive-compulsive symptoms/disorder (OCS/OCD). OCS prevalence was 39.6% and OCD prevalence was 27.5%. A significant correlation was found between OCD occurrence and PRS for CLZ metabolism (p=0.010 at pd=0.001), though this did not survive multiple testing correction. OCS severity positively correlated with clozapine treatment duration and PANSS general psychopathology subscale scores, but no associations were found with PRS for OCD, schizophrenia, or cross-disorder phenotypes.

Traits studied:CLZ/NorCLZ ratioClozapine metabolismNorclozapine metabolismObsessive-compulsive disorderObsessive-compulsive symptomsSchizophrenia
PubMedDOIMetascience Observatory

This variant is in our database but has no known associations or PRS memberships yet.

Gene information from NCBI Gene. Variant classifications from ClinVar.

Community Wiki

No community notes yet for this variant. Sign in to start one.

Comments

Sign in to join the discussion.

Loading comments…